Top Markets
#1 MowCat MowCat +48.86%
#2 Velvet Velvet +22.01%
#3 Derive Derive +20.28%
#4 Quack AI Quack AI +19.40%
#5 SkyAI SkyAI +14.51%
#6 Geodnet Geodnet +14.11%
#7 Bermuda Shorts Bermuda Shorts +14.08%
#8 aPriori aPriori +13.09%
#9 Audiera Audiera +12.67%
#10 Cross Cross +11.92%
Coin of the day
MowCat MowCat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Clasificación en acciones #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Precio por acción
$1.85
Última sincronización: 2024-08-19
Capitalización bursátil
$3.96M
Cambio (1 día)
2.78%
Cambio (1 año)
0.00%
País
US
Comercio MyMD Pharmaceuticals, Inc. (MYMD)

Categoría

Healthcare
Ganancias de MyMD Pharmaceuticals, Inc. (MYMD)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di MyMD Pharmaceuticals, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de MyMD Pharmaceuticals, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE